Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 12881

1.

Adjuvant ovarian suppression in premenopausal breast cancer.

Montemurro F, Perrone F, Geuna E.

N Engl J Med. 2015 Apr 23;372(17):1672-3. doi: 10.1056/NEJMc1502618#SA1. No abstract available.

PMID:
25901438
2.

Adjuvant ovarian suppression in premenopausal breast cancer.

Francis PA, Regan MM, Fleming GF.

N Engl J Med. 2015 Apr 23;372(17):1673. doi: 10.1056/NEJMc1502618. No abstract available.

3.

Breast cancer prevention in the era of precision medicine.

Narod SA.

J Natl Cancer Inst. 2015 Apr 8;107(5). pii: djv078. doi: 10.1093/jnci/djv078. Print 2015 May. No abstract available.

PMID:
25855708
4.

[Use of herbal medicine for cancer treatment-related toxicities].

Samuels N, Morag O, Maimon Y.

Harefuah. 2015 Jan;154(1):43-6, 67. Hebrew.

PMID:
25796675
5.

Co-targeting ER and HER family receptors induces apoptosis in HER2-normal or overexpressing breast cancer models.

Chakraborty AK, Mehra R, Digiovanna MP.

Anticancer Res. 2015 Mar;35(3):1243-50.

PMID:
25750271
6.

[Sentinel lymph node biopsy in male breast cancer - a case report].

Nishi T, Nishimura A, Morohashi S, Hakamada K.

Gan To Kagaku Ryoho. 2014 Nov;41(12):1972-4. Japanese.

PMID:
25731393
7.

[Long-term control of stage IV breast and gastric cancer with combination therapy of S-1 and paclitaxel].

Yamada C, Ishikawa F, Nitta H, Fujita Y, Omoto H, Kamata S, Ito H.

Gan To Kagaku Ryoho. 2014 Nov;41(12):1960-1. Japanese.

PMID:
25731389
8.

[A case of bone marrow carcinomatosis with disseminated intravascular coagulation arising from breast cancer successfully treated with paclitaxel plus bevacizumab].

Kawai H, Sugimoto R, Miyauchi S, Yoshida R, Waki N, Hirayama S, Ishizaki M, Nishi H, Yamashita K.

Gan To Kagaku Ryoho. 2014 Nov;41(12):1957-9. Japanese.

PMID:
25731388
9.

[A case of hyoid bone metastasis from breast cancer].

Kusama H, Okishiro M, Ishida T, Sato Y, Morimoto Y, Matsushita K, Hashimoto T, Kimura K, Katsura Y, Nitta K, Kagawa Y, Takeno A, Sakisaka H, Nakahira S, Taniguchi K, Egawa C, Takeda Y, Kato T, Tamura S, Takatsuka Y, Oku K, Goto T, Nagano T, Nakatsuka S.

Gan To Kagaku Ryoho. 2014 Nov;41(12):1915-7. Japanese.

PMID:
25731374
10.

[Environmental and genetic risk factors for endometrial carcinoma].

Sénéchal C, Cottereau E, de Pauw A, Elan C, Dagousset I, Fourchotte V, Gauthier-Villars M, Lae M, Stoppa-Lyonnet D, Buecher B.

Bull Cancer. 2015 Mar;102(3):256-69. doi: 10.1016/j.bulcan.2015.01.006. Epub 2015 Feb 26. Review. French.

PMID:
25725922
11.

Twenty-five years of breast cancer risk models and their applications.

Gail MH.

J Natl Cancer Inst. 2015 Feb 26;107(5). pii: djv042. doi: 10.1093/jnci/djv042. Print 2015 May. No abstract available.

PMID:
25722355
12.

Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence.

Blok EJ, Derks MG, van der Hoeven JJ, van de Velde CJ, Kroep JR.

Cancer Treat Rev. 2015 Mar;41(3):271-6. doi: 10.1016/j.ctrv.2015.02.004. Epub 2015 Feb 11. Review.

PMID:
25698635
13.

A prospective randomised study of transvaginal ultrasound effects of tamoxifen and exemestane in postmenopausal women with early breast cancer.

Garrone O, Bertelli G, Principe E, Lewis PD, Occelli M, Miraglio E, Merlano MC.

Tumori. 2014 Nov-Dec;100(6):620-4. doi: 10.1700/1778.19264.

PMID:
25688495
14.

Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer.

Nyante SJ, Sherman ME, Pfeiffer RM, Berrington de Gonzalez A, Brinton LA, Aiello Bowles EJ, Hoover RN, Glass A, Gierach GL.

J Natl Cancer Inst. 2015 Feb 6;107(3). pii: dju425. doi: 10.1093/jnci/dju425. Print 2015 Mar.

PMID:
25663687
15.

Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.

Thewes V, Simon R, Schroeter P, Schlotter M, Anzeneder T, Büttner R, Benes V, Sauter G, Burwinkel B, Nicholson RI, Sinn HP, Schneeweiss A, Deuschle U, Zapatka M, Heck S, Lichter P.

Cancer Res. 2015 Feb 15;75(4):720-31. doi: 10.1158/0008-5472.CAN-14-0652. Epub 2015 Feb 2.

PMID:
25643697
16.

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for tamoxifen pharmacogenetic studies.

Johnson JA, Hamadeh IS, Langaee TY.

J Natl Cancer Inst. 2015 Jan 31;107(2). pii: dju437. doi: 10.1093/jnci/dju437. Print 2015 Feb. No abstract available.

PMID:
25638249
17.

HER2 and β-catenin protein location: importance in the prognosis of breast cancer patients and their correlation when breast cancer cells suffer stressful situations.

Cuello-Carrión FD, Shortrede JE, Alvarez-Olmedo D, Cayado-Gutiérrez N, Castro GN, Zoppino FC, Guerrero M, Martinis E, Wuilloud R, Gómez NN, Biaggio V, Orozco J, Gago FE, Ciocca LA, Fanelli MA, Ciocca DR.

Clin Exp Metastasis. 2015 Feb;32(2):151-68. doi: 10.1007/s10585-015-9694-5. Epub 2015 Feb 1.

PMID:
25636904
18.

Treatment with adjuvant endocrine therapy for early-stage breast cancer: is it forever?

Overmoyer B.

J Clin Oncol. 2015 Mar 10;33(8):823-8. doi: 10.1200/JCO.2014.58.2361. Epub 2015 Jan 26. No abstract available.

PMID:
25624431
19.

Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.

Binkhorst L, Mathijssen RH, Jager A, van Gelder T.

Cancer Treat Rev. 2015 Mar;41(3):289-99. doi: 10.1016/j.ctrv.2015.01.002. Epub 2015 Jan 14. Review.

PMID:
25618289
20.

RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation.

McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, Sneige N, Moughan J, Shah A, Germain I, Hartford AC, Rashtian A, Walker EM, Yuen A, Strom EA, Wilcox JL, Vallow LA, Small W Jr, Pu AT, Kerlin K, White J.

J Clin Oncol. 2015 Mar 1;33(7):709-15. doi: 10.1200/JCO.2014.57.9029. Epub 2015 Jan 20.

PMID:
25605856
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk